Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis

Bradley Hall; James Padussis; Jason M. Foster

doi:10.1016/j.suc.2017.01.013

Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis

Bradley Hall, James Padussis, Jason M. Foster

Research output: Contribution to journal › Review article › peer-review

25 Scopus citations

Abstract

Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.

Original language	English (US)
Pages (from-to)	671-682
Number of pages	12
Journal	Surgical Clinics of North America
Volume	97
Issue number	3
DOIs	https://doi.org/10.1016/j.suc.2017.01.013
State	Published - Jun 2017

Keywords

CC score
Cytoreductive surgery (CRS)
Hyperthermic intraperitoneal chemotherapy (HIPEC)
Intraperitoneal chemotherapy (IP)
Peritoneal carcinoma index (PCI)
Peritoneal metastasis (PM)
R score

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.suc.2017.01.013

Cite this

@article{3a33b7a041064cf69ce965f8fd67f08b,

title = "Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis",

abstract = "Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.",

keywords = "CC score, Cytoreductive surgery (CRS), Hyperthermic intraperitoneal chemotherapy (HIPEC), Intraperitoneal chemotherapy (IP), Peritoneal carcinoma index (PCI), Peritoneal metastasis (PM), R score",

author = "Bradley Hall and James Padussis and Foster, {Jason M.}",

year = "2017",

month = jun,

doi = "10.1016/j.suc.2017.01.013",

language = "English (US)",

volume = "97",

pages = "671--682",

journal = "Surgical Clinics of North America",

issn = "0039-6109",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis

AU - Hall, Bradley

AU - Padussis, James

AU - Foster, Jason M.

PY - 2017/6

Y1 - 2017/6

N2 - Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.

AB - Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.

KW - CC score

KW - Cytoreductive surgery (CRS)

KW - Hyperthermic intraperitoneal chemotherapy (HIPEC)

KW - Intraperitoneal chemotherapy (IP)

KW - Peritoneal carcinoma index (PCI)

KW - Peritoneal metastasis (PM)

KW - R score

UR - http://www.scopus.com/inward/record.url?scp=85019255522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019255522&partnerID=8YFLogxK

U2 - 10.1016/j.suc.2017.01.013

DO - 10.1016/j.suc.2017.01.013

M3 - Review article

C2 - 28501254

AN - SCOPUS:85019255522

SN - 0039-6109

VL - 97

SP - 671

EP - 682

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

IS - 3

ER -

Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this